Over the past 12 months, 10 insiders at ARROWHEAD PHARMACEUTICALS, INC. filed 66 open-market SEC Form 4 transactions on ARWR: 0 purchases worth $0 and 66 sales worth $37.8M. Insiders have been net sellers over this period. The most recent filing was on May 12, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 12, 26 | Hongbo Lu | SELL | 3.0K | $76.88 | $228K |
| Apr 23, 26 | James C HamiltonChief Medical Officer | SELL | 10.0K | $75.00 | $750K |
| Apr 22, 26 | Daniel Joseph ApelChief Financial Officer | SELL | 8.7K | $71.92 | $628K |
| Mar 5, 26 | James C HamiltonChief Medical Officer | SELL | 10.0K | $64.19 | $642K |
| Jan 5, 26 | James C HamiltonChief Medical Officer | SELL | 14.8K | $68.00 | $932K |
| Jan 5, 26 | Patrick O'BrienCOO | SELL | 13.5K | $68.00 | $847K |
| Jan 2, 26 | Christopher Richard AnzaloneChief Executive Officer | SELL | 7.4K | $66.39 | $489K |
| Dec 29, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 35.2K | $69.33 | $2.4M |
| Dec 26, 25 | Mauro FerrariDirector | SELL | 7.5K | $70.00 | $527K |
| Dec 22, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 10.0K | $68.85 | $684K |
| Dec 19, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 8.1K | $68.48 | $554K |
| Dec 19, 25 | Adeoye Y OlukotunDirector | SELL | 6.1K | $68.48 | $414K |
| Dec 19, 25 | Victoria VakienerDirector | SELL | 5.3K | $68.39 | $359K |
| Dec 19, 25 | William D. WaddillDirector | SELL | 5.5K | $68.53 | $371K |
| Dec 17, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 46.3K | $66.30 | $2.9M |
| Dec 16, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 14.1K | $67.87 | $876K |
| Dec 15, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 100.5K | $69.96 | $6.9M |
| Dec 5, 25 | Michael S PerryDirector | SELL | 16.3K | $61.03 | $992K |
| Nov 28, 25 | Mauro FerrariDirector | SELL | 8.8K | $56.39 | $493K |
| Oct 1, 25 | James C HamiltonChief Medical Officer | SELL | 20.0K | $35.00 | $700K |
| Sep 12, 25 | James C HamiltonChief Medical Officer | SELL | 15.0K | $30.00 | $450K |
| Sep 2, 25 | James C HamiltonChief Medical Officer | SELL | 15.0K | $25.00 | $375K |
| Aug 15, 25 | James C HamiltonChief Medical Officer | SELL | 9.4K | $20.00 | $188K |
| Aug 13, 25 | James C HamiltonChief Medical Officer | SELL | 611 | $20.00 | $12K |
| Apr 11, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 50.8K | $11.49 | $584K |
| Apr 10, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 50.0K | $10.87 | $544K |
| Apr 9, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 35.3K | $11.76 | $351K |
| Mar 13, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 51.4K | $15.07 | $775K |
| Mar 4, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 133.3K | $17.02 | $2.3M |
| Mar 3, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 166.7K | $18.03 | $3.0M |
| Jan 23, 25 | Adeoye Y OlukotunDirector | SELL | 959 | $21.00 | $20K |
| Jan 7, 25 | Kenneth Allen MyszkowskiChief Financial Officer | SELL | 10.0K | $19.70 | $197K |
| Jan 7, 25 | Patrick O'BrienCOO and General Counsel | SELL | 8.0K | $19.69 | $158K |
| Jan 6, 25 | James C HamiltonChief Discovery/Trans Medicine | SELL | 21.8K | $20.11 | $428K |
| Jan 6, 25 | Kenneth Allen MyszkowskiChief Financial Officer | SELL | 17.8K | $20.10 | $350K |
| Jan 6, 25 | Patrick O'BrienCOO and General Counsel | SELL | 19.7K | $20.10 | $387K |
| Jan 2, 25 | Christopher Richard AnzaloneChief Executive Officer | SELL | 11.5K | $19.05 | $219K |
| Dec 27, 24 | Adeoye Y OlukotunDirector | SELL | 2.9K | $20.00 | $57K |
| Dec 23, 24 | Christopher Richard AnzaloneChief Executive Officer | SELL | 12.6K | $19.59 | $246K |
| Dec 18, 24 | Christopher Richard AnzaloneChief Executive Officer | SELL | 12.7K | $22.12 | $260K |
| Dec 17, 24 | Douglas B GivenDirector | SELL | 547 | $22.04 | $12K |
| Dec 17, 24 | William D. WaddillDirector | SELL | 3.7K | $22.04 | $83K |
| Dec 16, 24 | Douglas B GivenDirector | SELL | 5.0K | $21.90 | $110K |
| Dec 16, 24 | Victoria VakienerDirector | SELL | 9.0K | $21.91 | $197K |
| Dec 16, 24 | William D. WaddillDirector | SELL | 3.7K | $21.90 | $82K |
| Jul 2, 24 | Tracie OliverChief Commercial Officer | SELL | 9.4K | $25.28 | $237K |
| May 2, 24 | Victoria VakienerDirector | SELL | 1.8K | $23.31 | $42K |
| Apr 18, 24 | Hongbo LuDirector | BUY | 500 | $22.00 | $11K |
| Apr 10, 24 | Hongbo LuDirector | BUY | 500 | $25.00 | $13K |
| Apr 2, 24 | Hongbo LuDirector | BUY | 150 | $27.34 | $4K |
Over the past 12 months, insiders at ARROWHEAD PHARMACEUTICALS, INC. filed 0 open-market purchases worth $0 and 66 sales worth $37.8M on ARWR, which makes them net sellers over the period. The most recent Form 4 was filed on May 12, 26.
The largest recent open-market ARWR insider purchase in our data was $13K by Hongbo Lu, Director, filed on Apr 10, 24.
10 different insiders at ARROWHEAD PHARMACEUTICALS, INC. filed open-market SEC Form 4 transactions on ARWR over the last 12 months.
InsiderTape plots every ARWR insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every ARROWHEAD PHARMACEUTICALS, INC. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →